Brief: Transcode Therapeutics Files For Offering Of Up To 10 Mln Shares Of Common Stock
Brief: Transcode Therapeutics Inc Prices Public Offering Of 10 Million Shares Of Its Common Stock At $0.30 Per Share
Brief: TransCode Therapeutics Announces Proposed Public Offering Of Common Stock
Brief: Thomas A. Fitzgerald Reports 5.5% Stake In Transcode Therapeutics As Of June 14- SEC Filing
Brief: Transcode Therapeutics Has Regained Compliance With Minimum Bid Price Requirement Set Forth In Nasdaq Listing Rule 5550(A)(2)
Brief: TransCode Therapeutics Issues Open Letter to Shareholders
Brief: TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
Brief: Oncology Company TransCode Therapeutics Appoints Former Alopexx Exec Daniel Vlock As CMO
Brief: Nasdaq Determines Transcode Therapeutics Compliance With Minimum Stockholders’ Equity Requirement And Continued Listing
Brief: Transcode Therapeutics Files For Offering Up To 3.5 Million Shares Of Common Stock Together With Common Stock Purchase Warrants
Brief: Transcode Therapeutics Files For Offering Up To 1.5 Mln Shares Of Common Stock Together With Common Stock Purchase Warrants
TransCode Therapeutics gains on ongoing restructuring, CEO retirement
Brief: Transcode Therapeutics Inc - Plan To Submit IND To FDA In Q1 Of 2024
Brief: Transcode Therapeutics Reports Positive Pre-Clinical Results In Metastatic Pancreatic Cancer With Its Lead Candidate, TTX-MC138
Brief: TransCode Therapeutics Q3 operating income USD -5.3 million
Brief: Nasdaq Panel Grants Transcode Therapeutics Extension For Continued Listing
Brief: Transcode Therapeutics Announces Public Offering Of Common Stock
Brief: Transcode Therapeutics Announces Prolonged Survival In Murine Models With Glioblastoma Treated With Its Lead Candidate, Ttx-Mc138
Brief: Transcode Therapeutics Reports Prelim Results of Phase 0 Clinical Study With Lead Candidate